@abangelabs.bsky.socialA three-year colorectal screening model projects $12.5 million in savings, showing how budget impact analysis can guide adoption. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pubmed-next-generation-multitarget-stool-dna-idn-budget-model-2026-10-01
@drtimos.bsky.socialSignal or noise? > Cell Counting and Image Cytometry Reagents Market Forecast
to 2035, Driven by Cell and Gene Therapy Demand - IndexBox >> Comment below! #strategy #competitiveintelligence #marketing #biotech #healthcare #competitivemarketing #pharma #pharmaceutical
@abangelabs.bsky.socialPolpril Nebi secured positive Polish reimbursement advice after bioequivalence and budget review. https://www.mattheneus.com/editorial/aotmit-polpril-nebi-final-positive-advice-budget-savings-2026-10-01 #HTA #Pharma #RegulatoryAffairs
@pharmaphorum.bsky.socialIn today’s headlines: pharmaphorum.com/news #news #pharma #lifesciences #pharmanews #pharmaindustry
@midgardfinance.com📊 #pharma
🇩🇰 Novo Nordisk's semaglutide loses US exclusivity in December 2031. 🇺🇸 Eli Lilly's Mounjaro holds until June 2039.
7.5 years apart, on the two molecules the whole obesity market runs on.
$NOVO $LLY
@abangelabs.bsky.socialPBAC recommends Palynziq for phenylketonuria after revised pricing, showing how financial arrangements can unlock access. https://www.mattheneus.com/editorial/pbac-palynziq-final-outcome-financial-arrangement-2026-07 #HTA #Pharma #HealthEconomics
@aiinmeditech.bsky.socialHow is AI changing Medical Affairs?
From KOL identification and profiling to smarter engagement, AI-Powered KOL Intelligence is helping pharma teams turn complex data into actionable insights.
Read the full article: medium.com/@seosperreac...
@promptfoundry.bsky.socialA new arXiv paper introduces HyMLRaman, a hybrid framework combining EfficientNet-B3 embeddings with generative feature expansion to boost Raman spectroscopy identification of six common drug compounds.
#AI #RamanSpectroscopy #MachineLearning #Pharma
https://arxiv.org/abs/2610.02224
@abangelabs.bsky.socialEuropean regulators back Frehemgo for haemophilia A bleeding prophylaxis. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-frehemgo-denecimig-haemophilia-a-positive-opinion-fviii-mimetic-2026-09-17
@abangelabs.bsky.socialAustralia aligns Fabry disease enzyme therapies under one PBS reimbursement pathway. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pbac-agalsidase-alfa-beta-fabry-pbs-switching-framework-2026-07
@drtimos.bsky.socialSignal or noise? > Stocktwits Pharma Pulse: Roche Faces FDA Decision,
Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
- Yahoo Finance >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #competitivemarketing #healthcare
@abangelabs.bsky.socialThailand's access threshold for luspatercept points to a required 90.5% price reduction. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/thailand-luspatercept-price-threshold-budget-impact-2026-09-28
@abangelabs.bsky.socialFrance gives durvalumab a minor added-benefit rating in resectable gastric cancer.
#HTA #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialAustralia’s PBAC backs subcutaneous amivantamab at IV price parity, highlighting the HTA role of formulation bridging.
#HTA #Pharma #HealthEconomics
@drtimos.bsky.socialSignal or noise? > Gene therapy restored neural connections in adult dogs’
retinas — ScienceAlert - UA.NEWS >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #pharmaceutical #biotech
@markfortner.bsky.social"We're so close to the tech companies": Genentech CEO talks Fierce through vision for the future | #biotech #biotechsky #pharma
@pharmalot.bsky.social
@4040rec.bsky.social